ASX:ALAOE (Australia)
Â
Warrants (31/07/2022)
A$
0.01
(0%)
Jul 25
Business Description
Arovella Therapeutics Ltd
ISIN : AU0000182800
Share Class Description:
ASX:ALAOE: Warrants (31/07/2022)Description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 42.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.5 | |||||
| 3-Year EPS without NRI Growth Rate | 6.5 | |||||
| 3-Year FCF Growth Rate | 16.4 | |||||
| 3-Year Book Growth Rate | -16.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.44 | |||||
| Quick Ratio | 6.44 | |||||
| Cash Ratio | 6.23 | |||||
| Days Sales Outstanding | 939.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.8 | |||||
| Shareholder Yield % | -7.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -60061.11 | |||||
| Net Margin % | -48588.89 | |||||
| ROE % | -144.63 | |||||
| ROA % | -108.94 | |||||
| ROIC % | -2671.58 | |||||
| ROC (Joel Greenblatt) % | -7894.88 | |||||
| ROCE % | -144.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 15.91 | |||||
| EV-to-EBIT | -20.82 | |||||
| EV-to-EBITDA | -20.92 | |||||
| EV-to-Revenue | 10106.56 | |||||
| EV-to-FCF | -25.83 | |||||
| Earnings Yield (Greenblatt) % | -4.8 | |||||
| FCF Yield % | -3.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arovella Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (A$) | 0 | ||
| 20-Day SMA (A$) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (A$) | 0.005 - 0.005 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arovella Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arovella Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arovella Therapeutics Ltd Frequently Asked Questions
What is Arovella Therapeutics Ltd(ASX:ALAOE)'s stock price today?
The current price of ASX:ALAOE is A$0.01. The 52 week high of ASX:ALAOE is A$0.01 and 52 week low is A$0.01.
When is next earnings date of Arovella Therapeutics Ltd(ASX:ALAOE)?
The next earnings date of Arovella Therapeutics Ltd(ASX:ALAOE) is 2025-02-28 Est..
Does Arovella Therapeutics Ltd(ASX:ALAOE) pay dividends? If so, how much?
Arovella Therapeutics Ltd(ASX:ALAOE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers